Thus, there is potential for targeting CBP/p300-altered cancers with CARM1i or a combination of CARM1 and CBP/p300 inhibitors in specific cancers in which residual CBP/p300 expression is required for survival, as in DLBCL. Here, CARM1 is linked to cancer.